World Journal of Analytical Chemistry
ISSN (Print): 2333-1178 ISSN (Online): 2333-1283 Website: http://www.sciepub.com/journal/wjac Editor-in-chief: Raluca-Ioana Stefan-van Staden
Open Access
Journal Browser
Go
World Journal of Analytical Chemistry. 2016, 4(1), 11-16
DOI: 10.12691/wjac-4-1-3
Open AccessArticle

Spectrophotometry Method for the Determination of Terazosin in Tablet Formulation

Alankar Shrivastava1, and Lalita Dhakad2

1Department of Pharmaceutics, Institute of Biomedical Education and Research, Mangalayatan University, Beswan, Aligarh, India

2B.R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur (M.P), India

Pub. Date: May 11, 2016

Cite this paper:
Alankar Shrivastava and Lalita Dhakad. Spectrophotometry Method for the Determination of Terazosin in Tablet Formulation. World Journal of Analytical Chemistry. 2016; 4(1):11-16. doi: 10.12691/wjac-4-1-3

Abstract

Terazosin (TRZ) is indicated in the symptomatic relief of benign prostatic hyperplasia. The presented study is spectrophotometry method for the determination of terazosin in tablet dosage forms. Bromophenol blue was used for ion pair complex with the drug in 1:1 ratio. The linear range, limit of detection (LOD) and limit of quantitation (LOQ) were found to be 1-10, 0.001 and 0.012 μg/ml respectively. The method was found to be specific when applied with some excipients and accurate enough to be applied in tablet formulation.

Keywords:
Terazosin Spectrophotometry method validation ICH guidelines Bromophenol blue

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Cornu, J.N. “Current advances in male lower urinary tract symptoms assessment and management: more and more questions.” Curr Opin Urol. 2016 Jan,26(1), 1-2.
 
[2]  Yuan, J.Q., Mao, C., Wong, S.Y., Yang, Z.Y., Fu, X.H., Dai, X.Y., Tang, J.L. “Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.” Medicine (Baltimore). 2015, 94(27), e974.
 
[3]  Kim, E.H., Larson, J.A., Andriole, G,L. “Management of Benign Prostatic Hyperplasia.” Annu. Rev. Med. 2016, 67, 8.1-8.15. doi: 10.1146/annurev-med-063014-123902.
 
[4]  Shrivastava, A. “Various Analytical Methods for the Determination of Terazosin in Different Matrices.” World J Analy Chem, 2013, 1(4), 80-86.
 
[5]  European Pharmacopoeia. European Directorate for the Quality of Medicines. Strasbourg, 2007.
 
[6]  USP29-NF24, Pharmacopeial Forum : Volume No. 29(5) Page 1580.
 
[7]  Terazosin hydrochloride dehydrate. British Pharmacopoeia. 2012.
 
[8]  Sonders, R,C. “Pharmacokinetics of terazosin.” Am J Med. 1986, 80(5B), 20-4.
 
[9]  Wilde, M.I., Fitton, A., Sorkin, E.M. “Terazosin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Benign Prostatic Hyperplasia.” Drugs & Aging 1993, 3(3), 258-277.
 
[10]  Titmarsh, S., Monk, J.P. “Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.” Drugs. 1987; 33(5):461-77.
 
[11]  Nirmalani-Gandhy, A., Sanchez, D., Catalano, G. “Terazosin for the treatment of trauma-related nightmares: a report of 4 cases.” Clin Neuropharmacol. 2015, 38(3), 109-11.
 
[12]  Shrivastava, A., Saxena, P., Gupta, V.B. “Spectrophotometric estimation of tamsulosin hydrochloride by acid-dye method.” Pharm Methods. 2011, 2(1), 53-60.
 
[13]  ICH Q2B. Validation of Analytical Procedures: Methodology (International Conference on Harmonization of Technical Requirements for the Registration of Drugs For Human Use, Geneva, Switzerland, May 1997).
 
[14]  Sankar, V., Raghuraman, S., Sivanand, V., Ravichandran, V., “Spectrophotometric method for the estimation of Terazosin in Tablets.” Ind J Pharm Sci, 2000, 61(6): 463-464.
 
[15]  Prasad, C.V.N., Gautham, A., Bhardwaj, V., Praimoo, P. “Quantitative determination of Terazosin HCl in tablet preparation by fluorimetry”. Ind J Pharm Sci, 1998, 60(3), 167-9.
 
[16]  Zeeb, M., Sadeghi, M., “Sensitive Determination of Terazosin in Pharmaceutical Formulations and Biological Samples by Ionic-Liquid Microextraction Prior to Spectrofluorimetry.” Inter J Anal Chem 2012, 1-7.
 
[17]  Jiang, C.J., Gao, M.X., He, J.X., “Study of the interaction between terazosin and serum albumin synchronous fluorescence determination of terazosin.” Anal Chim Acta, 2002, 452, 185-189.
 
[18]  Wang, C.C., Luconi, M.O., Masi, A.N., Fernández, L., “Determination of terazosin by cloud point extraction-fluorimetric combined methodology.” Talanta, 2007, 72(5), 1779-85.
 
[19]  Abdine, H.H., El-Yazbi, F.A., Blaih, S.M., Shaalan, R.A., “Spectrophotometric and spectrofluorimetric methods for the determination of terazosin in dosage forms.” Spectrosc Lett: Int J Rapid Communication, 1998, 31(5), 969-980.
 
[20]  El, Sheikh., R., Esmail, N.S., Gouda, A.A., Basset, W.A., “Extractive spectrophotometric determination of some α-adrenergic antagonists in pure forms and in pharmaceutical formulations.” CI & CEQ, 2012, 18(2), 179-191.
 
[21]  Ismail, N.S., Mohamed, T.A. “Potentiometric and Fluorimetric Methods for the Determination of Terazosin HCl in Drug Substance and Dosage Forms.” Int. J. Electrochem. Sci., 2014, 9, 7394-7413.
 
[22]  Shrivastava, A., Gupta, V.B., “Ultra violet spectrophotometric method: Not possible for the simultaneous estimation of alpha one adrenoreceptor blockers.” J Pharm Negative Results, 2011, 2, 115-120.
 
[23]  Mohamed, T.A., Ismail, N.S. “Fluorimetric Methods for the Determination of Terazosin HCl in Drug Substance and Dosage Forms.” Iranian J Pharma Sci. 2014, 10 (1), 15-26.
 
[24]  Setty, K.N., Reddy, G.V.R., Reddy, N.R. “Spectrophotometric determination of terazosin in tablet dosage forms.” World J Pharma Res 2014, 4(1), 875-881.
 
[25]  Taguchi, K., Scha¨fers, R.F., Michel, M.C., “Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.” Br J Clin Pharmacol, 1998, 45, 49-55.
 
[26]  Cheah, P.Y., Yuena, K.H., Liong, M.L. “Improved high performance liquid chromatographic analysis of terazosin in human plasma.” J Chromatogr B, 2000, 745, 439-443.
 
[27]  Zavitsanos, A.P., Alebic-Kolbah, T., “Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography–electrospray mass spectrometry.” J Chromatogr A, 1998, 794, 45-56.
 
[28]  Zou, H.Y., Wu, H.L., Ou Yang, L.Q., Zhang, Y., Nie, J.F., Fu, H.Y., Yu RQ., “Fluorescent quantification of terazosin hydrochloride content in human plasma and tablets using second-order calibration based on both parallel factor analysis and alternating penalty trilinear decomposition.” Analy Chim Acta, 2009, 650, 143-149.
 
[29]  Bauer, J.F., Krogh, S.K, Chang, Z.L., Wong, C.F., “Determination of minor impurities in terazosin by high performance liquid chromatography.” J Chromatography, 1993, 648, 175-181.
 
[30]  Bakshi, M., Ojha, T., Singh, S., “Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.” J Pharm Biomed Anal 2004, 34, 19-2.
 
[31]  Ojha, T., Bakshi, M., Chakraborti, A.K., Singh, S., “The ICH guidance in practice: stress decomposition studies on three piperazinyl quinazoline adrenergic receptor-blocking agents and comparison of their degradation behaviour.” J Pharm Biomed Anal, 2003, 31, 775-783.
 
[32]  EY Oh, SK Bae, JW Kwon, M You, DC Lee, MG Lee. Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. Br J Clin Pharmacol, 2007, 151, 24-34.
 
[33]  Wei, X., Yin, J., Yang, G., He, C., Chen, Y., “On-line solid-phase extraction with a monolithic weak cation-exchange column and simultaneous screening of α1-adrenergic receptor antagonists in human plasma.” J Sep Sci, 2007, 30, 2851-2857.
 
[34]  Chen, D., Zhao, C., “Determination of Terazosin in Human Plasma by High performance Liquid Chromatography with Ultraviolet Detection.” Asian J Traditional Med. 1-3.
 
[35]  Shrivastava, A., Gupta, V.B., “Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations.” Sci Pharm, 2012, 80, 619-631.
 
[36]  Shrivastava, A., Gupta, V.B., “Simultaneous Determination of Two Alpha-One Adrenoreceptor Blockers Terazosin and Prazosin Using Tamsulosin as Internal Standard.” Inter J Pharm Pharma Sci, 2012, 4(3), 752-756.
 
[37]  Ahmed, S., Mohamed, N.A., El Zohny, S.A. “A sensitive and reliable method for therapeutic monitoring of α1-blockers in rabbit plasma by ion-pair chromatography with enhanced fluorescence detection.” Microchemical J. 2015.
 
[38]  Li, A.P., Peng, H., Peng, J.D., Zhou, M.Q., Zhang, J. “Rayleigh light scattering detection of three α1-adrenoceptor antagonists coupled with high performance liquid chromatograph.” Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.Spectrochim Acta A Mol Biomol Spectrosc.2015 Aug 5; 147: 178-84.
 
[39]  Zadeh, S.E., Qomi, M., Saadat, M.R., Piroozi, F. “Three-Phase Hollow fiber Liquid-Phase Micro Extraction for Determination and Analysis of Terazosin in Biological Fluids via High Performance Liquid Chromatography at Trace Levels.” Current Analytical Chemistry. 2016, 12(6), 1-7.
 
[40]  Shrivastava, A., Gupta, V.B., “Validated HPLC and HPTLC Methods for Simultaneous Determination of Some α1-Adrenoreceptor Blockers.” Lat Am J Pharm, 2012, 31(2), 279-86.
 
[41]  Chang Zui, L., Bauer, J.F. “Analytical Profile of Drug Substances”, 20th volume, Academic Press, Elsevier; 2005, 717-720.
 
[42]  Shrivastava, A., Patel, A., Gupta, V.B., “Stability Indicating HPTLC Determination of Terazosin in Tablet Formulation, World J Anal Chem, 2013, 1(3), 31-36.
 
[43]  Belal, T.S., Mahrous, M.S., Abdel-Khalek, M.M., Daabees, H.G., Khamis, M.M. “Validated HPTLC method for the simultaneous determination of alfuzosin, terazosin, prazosin, doxazosin and finasteride in pharmaceutical formulations.” Analytical Chemistry Research 2014;1:23-31.
 
[44]  Mohamed, N.A., Ahmed, S., El Zohny, S.A. “A Specific High-Performance Thin-Layer Chromatography with Fluorescence Detection for the Determination of Some α1-Blockers” J Liquid Chromatogr & Related Technologies, 2015;38:2:271-282.
 
[45]  Badawey, A.M., Abd El-Aleem, A.E.B., Lamie, N.T., “Membrane sensors for the selective determination of terazosin hydrochloride dihydrate in presence of its degradation product.” Inter J Comp Pharm, 2011, 2(7), 1-5.
 
[46]  Ganjali, M.R., Faridbod, F., Larijani, B., Riahi, S., Hosseini, M., Nasli-Esfahani, E et al. Terazosin potentiometric sensor for quantitative analysis of terazosin hydrochloride in pharmaceutical formulation based on computational study. Int. J. Electrochem. Sci., 2010, 5, 200-214.
 
[47]  Atta, N.F., Darwish, S.A., Khalil, S.E., Galal, A. “Effect of surfactants on the voltammetric response and determination of an antihypertensive drug.” Talanta 2007, 72, 1438-1445.
 
[48]  Zayed, S.I.M., Khalil, M.M., Issa, Y.M., Khalefa, H.R. “Flow Injection Potentiometric Determination of Terazosin Hydrochloride Using Modified Carbon Paste Electrodes.” Int. J. Electrochem. Sci., 2014, 9, 2327-2340.
 
[49]  Madrakian, T., Ghasemi, H., Afkhamia, A. “Haghshenas E. ZnO/rGO nanocomposite/carbon paste electrode for determination of terazosin in human serum samples” RSC Adv., 2016, 6, 2552-2558.